Pyloric Pseudonecrosis Caused by Biliary Peritonitis: A Rare Intraoperative Pitfall. [PDF]
Mouawad C, Eid D, Dager N.
europepmc +1 more source
Prospective randomised double‐blind trial: holmium laser lithotripsy with vs without Moses™ 2.0
Objective To assess the effect of Moses™ 2.0 (Lumenis Be Ltd., Yokneam Illit, Israel; Boston Scientific, Marlborough, MA, USA) for lithotripsy of renal stones of 8–20 mm in diameter on operative time, surgeon workload, and retropulsion. Subjects/Patients and Methods In our multicentre, randomised, double‐blind clinical trial, patients were randomised 1:
Kimberly A. Maciolek +19 more
wiley +1 more source
Internal herniation through Petersen's defect following Roux-en-Y gastric bypass presenting as subacute bilateral lower extremity edema due to IVC compression - a case report. [PDF]
Bryan R, Garcia S, Khorgami Z.
europepmc +1 more source
This study evaluated the Total Abnormality Score (TAS) from cMRI at term‐equivalent age as a predictor of cerebral palsy (CP) in 137 infants born preterm or with low birthweight. Infants who developed CP had significantly higher TAS values (median 11 vs 2), with a TAS cut‐off of 9.5 demonstrating high sensitivity (88.9%) and specificity (91.4%) for CP ...
Anne‐Kathrin Dathe +6 more
wiley +1 more source
ABSTRACT Aims Real‐world long‐term data on oral semaglutide are limited. We evaluated its 24‐month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D). Materials and Methods This retrospective real‐world study included 232 adults with T2D initiating oral semaglutide at an Italian diabetes clinic.
Maria Pompea Antonia Baldassarre +6 more
wiley +1 more source
Gastrointestinal complications of cocaine use: a narrative literature review. [PDF]
Qasim A +4 more
europepmc +1 more source
Urgent Reno-Hepatic Artery Bypass for Acute on Chronic Mesenteric Ischemia Following Robotic Low Anterior Resection for Rectal Cancer in a Patient with Severe Stenosis of the Hepatosplenomesenteric Trunk. [PDF]
Hanada K +4 more
europepmc +1 more source
GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists provide benefits in weight reduction, glycaemic control in Type 2 diabetes, and cardiovascular and renal outcomes. Their widespread use has given rise to concerns regarding rare but potentially serious adverse events.
Peter Ueda
wiley +1 more source
Development and internal validation of a prediction model for early anastomotic leak after minimally invasive esophagectomy: a prospective cohort study. [PDF]
Feng ZB +8 more
europepmc +1 more source
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi +9 more
wiley +1 more source

